Vivos Inc. Provides 2020 Recap and Outlines 2021 Objectives
28 janv. 2021 09h30 HE
|
Vivos Inc.
Richland WA, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), provides 2020 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2021, I think it is...
Vivos Inc Receives Feedback from FDA on Breakthrough Designation Request
19 janv. 2021 09h30 HE
|
Vivos Inc.
Richland WA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Although we were unable to secure a Breakthrough Device Designation from the FDA, this was a well-designed process that...
Vivos Inc Completes Surrogate Lymph Node Testing Using Mouse Spleen Injections Demonstrating Uniform Perfusion and Stability
09 déc. 2020 09h30 HE
|
Vivos Inc.
Richland WA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it worked with Mayo Clinic doctors to design and then conduct tests on the...
Vivos Inc to Present at The 13th Annual LD Micro Main Event Conference December 15, 2020 11:00 AM Eastern Standard Time
07 déc. 2020 09h30 HE
|
Vivos Inc.
Richland WA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL``), Vivos Inc (RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of...
Vivos Inc Extends it Intellectual Property Protection
01 déc. 2020 09h30 HE
|
Vivos Inc.
Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent...
Vivos Inc Applies for Breakthrough Device Designation for Radiogel™
20 nov. 2020 09h30 HE
|
Vivos Inc.
Richland WA, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced that it has completed its submission to the FDA seeking Breakthrough Device Designation for Radiogel™. ...
Vivos Inc Initiates IsoPet Therapy of Horses – Addressing Unmet Need for the Treatment of Equine Tumors
03 sept. 2020 09h30 HE
|
Vivos Inc.
Richland WA, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce today that it is expanding Isopet® into the equine market by making IsoPet® available to...
Vivos Inc Provides Update on Initial Indication for Use for RadioGelTM Therapy
26 août 2020 09h30 HE
|
Vivos Inc.
Richland WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), We are excited to announce that based on the recommendation of our Medical Advisory Board, Vivos Inc has decided on treating...
Vivos Inc Reports Additional IsoPet Therapies
30 juil. 2020 07h00 HE
|
Vivos Inc.
Richland WA, July 30, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Interest in IsoPet therapy is increasing. Yesterday Vivos Inc treated “Mister Motto” a cat that the pet parents flew to the...
Vivos Inc Receives Grant of Protection for RadioGel™ Therapy in China
22 juil. 2020 07h00 HE
|
Vivos Inc.
Richland WA, July 22, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos announced it received the Grant of Protection for the Radiogel™ trademark application in China. The mark is now...